Benoit Coutu
Overview
Explore the profile of Benoit Coutu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
894
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stambler B, Coutu B, Ip J, Mondesert B, Pandey A, Sager P, et al.
Circ Arrhythm Electrophysiol
. 2024 Nov;
17(12):e011681.
PMID: 39601141
No abstract available.
2.
Vella A, Greiss I, Mansour F, Lakkis B, Joly P, Coutu B
HeartRhythm Case Rep
. 2024 Jul;
10(6):402-405.
PMID: 38983899
No abstract available.
3.
Ip J, Coutu B, Noseworthy P, Parody M, Rafii F, Sears S, et al.
J Am Coll Cardiol
. 2024 Mar;
83(20):2032-2034.
PMID: 38537917
No abstract available.
4.
Lakkis B, Mansour F, Joly P, Vella A, Coutu B
HeartRhythm Case Rep
. 2024 Feb;
10(2):166-168.
PMID: 38404969
No abstract available.
5.
Ip J, Bui H, Camm A, Coutu B, Noseworthy P, Parody M, et al.
Am Heart J
. 2024 Jan;
270:55-61.
PMID: 38266665
Background: Paroxysmal supraventricular tachycardia (PSVT) is a common episodic arrhythmia characterized by unpredictable onset and burdensome symptoms including palpitations, dizziness, chest pain, distress, and shortness of breath. Treatment of acute...
6.
Ip J, Coutu B, Bennett M, Pandey A, Stambler B, Sager P, et al.
J Am Heart Assoc
. 2023 Sep;
12(19):e028227.
PMID: 37753718
Background Self-administration of investigational intranasal L-type calcium channel blocker etripamil during paroxysmal supraventricular tachycardia (PSVT) appeared safe and well-tolerated in the phase 3 NODE-301 (Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Efficacy, and...
7.
Han H, Wang J, Birnie D, Alings M, Philippon F, Parkash R, et al.
JAMA Cardiol
. 2023 Apr;
8(5):484-491.
PMID: 37017943
Importance: Cardiac implantable electronic device (CIED) infection is a potentially devastating complication with an estimated 12-month mortality of 15% to 30%. The association of the extent (localized or systemic) and...
8.
Stambler B, Plat F, Sager P, Shardonofsky S, Wight D, Potvin D, et al.
Circ Arrhythm Electrophysiol
. 2022 Nov;
15(12):e010915.
PMID: 36441560
Background: Pharmacologic termination of paroxysmal supraventricular tachycardia (PSVT) often requires medically supervised intervention. Intranasal etripamil, is an investigational fast-acting, nondihydropyridine, L-type calcium channel blocker, designed for unsupervised self-administration to terminate...
9.
Longtin Y, Gervais P, Birnie D, Wang J, Alings M, Philippon F, et al.
Open Forum Infect Dis
. 2021 Dec;
8(11):ofab513.
PMID: 34859113
Background: The Prevention of Arrhythmia Device Infection Trial (PADIT) investigated whether intensification of perioperative prophylaxis could prevent cardiac implantable electronic device (CIED) infections. Compared with a single dose of cefazolin,...
10.
Kumar S, Davis J, Thibault B, Mangat I, Coutu B, Bennett M, et al.
Europace
. 2021 Feb;
23(8):1319-1323.
PMID: 33608700
Aims: Cardiac implantable electronic devices with device advisories have the potential of device malfunction. Remote monitoring (RM) of devices has been suggested to allow the identification of abnormal device performance...